Oral submucous fibrosis: pathogenesis and therapeutic approaches

Abstract

Oral submucous fibrosis (OSF), characterized by excessive deposition of extracellular matrix (ECM) that causes oral mucosal tissue sclerosis, and even cancer transformation, is a chronic, progressive fibrosis disease. However, despite some advancements in recent years, no targeted antifibrotic strategies for OSF have been approved; likely because the complicated mechanisms that initiate and drive fibrosis remain to be determined. In this review, we briefly introduce the epidemiology and etiology of OSF. Then, we highlight how cell-intrinsic changes in significant structural cells can drive fibrotic response by regulating biological behaviors, secretion function, and activation of ECM-producing myofibroblasts. In addition, we also discuss the role of innate and adaptive immune cells and how they contribute to the pathogenesis of OSF. Finally, we summarize strategies to interrupt key mechanisms that cause OSF, including modulation of the ECM, inhibition of inflammation, improvement of vascular disturbance. This review will provide potential routes for developing novel anti-OSF therapeutics.

References

[1] Warnakulasuriya S, et al.. Oral potentially malignant disorders: a consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer. Oral. Dis., 2021, 27: 1862-1880.

[2] Warnakulasuriya S, et al.. Areca nut and oral cancer: evidence from studies conducted in humans. J. Dent. Res, 2022, 101: 1139-1146.

[3] Sirsat SM, et al.. Submucous fibrosis of the palate in diet-preconditioned Wistar rats. Induction by local painting of capsaicin-an optical and electron microscopic study. Arch. Pathol., 1960, 70: 171-179

[4] Pindborg JJ, et al.. Frequency of oral carcinoma, leukoplakia, leukokeratosis, leukoedema, submucous fibrosis, and lichen planus in 10,000 Indians in Lucknow, Uttar Pradesh, India; preliminary report. J. Dent. Res., 1965, 44: 61.

[5] Wahi PN, et al.. Submucous fibrosis of the oral cavity. 2. Studies on epidemiology. Bull. World Health Organ., 1966, 35: 793-799

[6] Shiau YY, et al.. Submucous fibrosis in Taiwan. Oral. Surg. Oral. Med. Oral. Pathol., 1979, 47: 453-457.

[7] Canniff JP, et al.. The aetiology of oral submucous fibrosis: the stimulation of collagen synthesis by extracts of areca nut. Int. J. Oral. Surg., 1981, 10: 163-167

[8] Harvey W, et al.. Stimulation of human buccal mucosa fibroblasts in vitro by betel-nut alkaloids. Arch. Oral. Biol., 1986, 31: 45-49.

[9] Murti PR, et al.. Effect on the incidence of oral submucous fibrosis of intervention in the areca nut chewing habit. J. Oral. Pathol. Med., 1990, 19: 99-100.

[10] Misra SP, et al.. Oesophageal subepithelial fibrosis: an extension of oral submucosal fibrosis. Postgrad. Med. J., 1998, 74: 733-736.

[11] Chiang CP, et al.. Quantitative analysis of immunocompetent cells in oral submucous fibrosis in Taiwan. Oral. Oncol., 2002, 38: 56-63.

[12] Chiu CJ, et al.. Interaction of collagen-related genes and susceptibility to betel quid-induced oral submucous fibrosis. Cancer Epidemiol. Biomark. Prev., 2002, 11: 646-653

[13] Li X, et al.. Effect of arecoline on the differentiation of myofibroblasts of oral mucosa. Chin. J. Stomatol., 2007, 42: 423-427

[14] Moutasim KA, et al.. Betel-derived alkaloid up-regulates keratinocyte alphavbeta6 integrin expression and promotes oral submucous fibrosis. J. Pathol., 2011, 223: 366-377.

[15] Khan I, et al.. Role of TGF-β and BMP7 in the pathogenesis of oral submucous fibrosis. Growth Factors, 2011, 29: 119-127.

[16] Pant I, et al.. Role of areca nut induced TGF-β and epithelial-mesenchymal interaction in the pathogenesis of oral submucous fibrosis. PLoS One, 2015, 10: e0129252.

[17] Li J, et al.. YAP-induced endothelial-mesenchymal transition in oral submucous fibrosis. J. Dent. Res., 2019, 98: 920-929.

[18] Yao M, et al.. Role of the arecoline/YAP1/BMP4 pathway in promoting endothelial-mesenchymal transition in oral submucous fibrosis. J. Oral. Pathol. Med., 2020, 49: 305-310.

[19] Xie C, et al.. Identification of a BRAF/PA28γ/MEK1 signaling axis and its role in epithelial-mesenchymal transition in oral submucous fibrosis. Cell Death Dis., 2022, 13. 701

[20] Chou MY, et al.. MiR-424/TGIF2-mediated pro-fibrogenic responses in oral submucous fibrosis. Int. J. Mol. Sci., 2023, 24: 5811.

[21] Yu CH, et al.. XIST/let-7i/HMGA1 axis maintains myofibroblasts activities in oral submucous fibrosis. Int. J. Biol. Macromol., 2023, 232. 123400

[22] Gupta PC, et al.. Global epidemiology of areca nut usage. Addict. Biol., 2002, 7: 77-83.

[23] Yuwanati M, et al.. Prevalence of oral submucous fibrosis among areca nut chewers: a systematic review and meta-analysis. Oral. Dis., 2023, 29: 1920-1926.

[24] Cai X, et al.. Oral submucous fibrosis: a clinicopathological study of 674 cases in China. J. Oral. Pathol. Med., 2019, 48: 321-325.

[25] Singh AK, et al.. Prevalence and risk factors for oral potentially malignant disorders in Indian population. J. Pharm. Bioallied Sci., 2021, 13: S398-s401.

[26] Reichart P, et al.. Betel quid chewing, oral cancer and other oral mucosal diseases in Vietnam: a review. J. Oral. Pathol. Med., 2008, 37: 511-514.

[27] Zhang S, et al.. Betel-quid and oral submucous fibrosis: a cross-sectional study in Hunan province, China. J. Oral. Pathol. Med., 2012, 41: 748-754.

[28] Gupta S, et al.. Oral submucous fibrosis: an overview of a challenging entity. Indian J. Dermatol. Venereol. Leprol., 2021, 87: 768-777.

[29] Kujan O, et al.. Malignant transformation of oral submucous fibrosis: a systematic review and meta-analysis. Oral. Dis., 2021, 27: 1936-1946.

[30] Murthy V, et al.. Malignant transformation rate of oral submucous fibrosis: a systematic review and meta-analysis. J. Clin. Med., 2022, 11: 1793.

[31] Xinchun J, et al.. Oral submucous fibrosis transforming into squamous cell carcinoma: a prospective study over 31 years in mainland China. Clin. Oral. Investig., 2020, 25: 2249-2256

[32] Pindborg JJ. Frequency of oral submucous fibrosis in North India. Bull. World Health Organ., 1965, 32: 748-750

[33] Murti PR, et al.. Malignant transformation rate in oral submucous fibrosis over a 17-year period. Community Dent. Oral. Epidemiol., 1985, 13: 340-341.

[34] International Agency for Research on Cancer. IARC monographs on the Identification of Carcinogenic Hazards to Humans. Vol. 85, 1–334 (International Agency for Research on Cancer, 2004).

[35] Cirillo N, et al.. Are there betel quid mixtures less harmful than others? A scoping review of the association between different betel quid ingredients and the risk of oral submucous fibrosis. Biomolecules, 2022, 12: 664.

[36] Liu YJ, et al.. The pharmacology, toxicology and potential applications of arecoline: a review. Pharm. Biol., 2016, 54: 2753-2760.

[37] Pentenero M, et al.. Chronic mechanical trauma/irritation and oral carcinoma: a systematic review showing low evidence to support an association. Oral. Dis., 2022, 28: 2110-2118.

[38] Yang B, et al.. Rat model with oral submucous fibrosis induced by arecoline and mechanical stimulation. West Chin. J. Stomatol., 2019, 37: 260-264

[39] Chen HM, et al.. HLA typing in Taiwanese patients with oral submucous fibrosis. J. Oral. Pathol. Med., 2004, 33: 191-199.

[40] CW VW, et al.. HLA-antigens in oral submucous fibrosis. J. Oral. Pathol. Med, 1994, 23: 23-27.

[41] Liu CJ, et al.. Polymorphism of the MICA gene and risk for oral submucous fibrosis. J. Oral. Pathol. Med., 2004, 33: 1-6.

[42] Jeevankumar S, et al.. Association of MICA gene Exon-5 polymorphism in oral submucous fibrosis. Oral. Surg. Oral. Med., Oral. Pathol. Oral. Radiol., 2023, 135: 110-116.

[43] Shin YN, et al.. Association of CTLA-4 gene polymorphism with oral submucous fibrosis in Taiwan. J. Oral. Pathol. Med., 2004, 33: 200-203.

[44] Agrawal D, et al.. Role of GSTM1 and GSTT1 polymorphism: susceptibility to oral submucous fibrosis in the North Indian population. Oncology, 2010, 79: 181-186.

[45] Chaudhary AK, et al.. Synergistic effect of stromelysin-1 (matrix metalloproteinase-3) promoter (-1171 5A->6A) polymorphism in oral submucous fibrosis and head and neck lesions. BMC Cancer, 2010, 10. 369

[46] Li N, et al.. Novel genetic biomarkers for susceptibility to oral submucous fibrosis: cytochrome P450 3A. Med. Hypotheses, 2011, 77: 834-836.

[47] Chaudhuri SR, et al.. CYP1AI and CYP2E1 gene polymorphisms may increase susceptibility to oral submucous fibrosis among betel quid chewers of eastern India. Gene, 2013, 513: 268-271.

[48] Adhvaryu SG, et al.. SCE frequencies in lymphocytes of tobacco/betel nut chewers and patients with oral submucous fibrosis. Br. J. Cancer, 1986, 53: 141-143.

[49] Jeyapradha D, et al.. Comparison of the frequency of sister chromatid exchange in pan chewers and oral submucous fibrosis patients. J. Oral. Maxillofac. Pathol., 2011, 15: 278-282.

[50] Desai SS, et al.. Cytogenetic damage in exfoliated oral mucosal cells and circulating lymphocytes of patients suffering from precancerous oral lesions. Cancer Lett., 1996, 109: 9-14.

[51] Joshi MS, et al.. Cytogenetic alterations in buccal mucosa cells of chewers of areca nut and tobacco. Arch. Oral. Biol., 2011, 56: 63-67.

[52] Paulose S, et al.. Estimation of serum malondialdehyde and assessment of DNA damage using comet assay in patients with oral submucous fibrosis. J. Investig. Clin. Dent., 2016, 7: 286-293.

[53] Sachdev PK, et al.. Zinc, copper, and iron in oral submucous fibrosis: a meta-analysis. Int. J. Dent., 2018, 2018. 3472087

[54] Ma RH, et al.. Increased lysyl oxidase activity in fibroblasts cultured from oral submucous fibrosis associated with betel nut chewing in Taiwan. J. Oral. Pathol. Med., 1995, 24: 407-412.

[55] Trivedy C, et al.. Copper content in Areca catechu (betel nut) products and oral submucous fibrosis. Lancet, 1997, 349: 1447.

[56] Mehrotra R, et al.. Lipid profile in oral submucous fibrosis. Lipids Health Dis., 2009, 8: 29.

[57] Kanthem RK, et al.. Serum lipid profile in oral submucous fibrosis: a clinico pathological study. J. Oral. Maxillofac. Pathol., 2015, 19: 139-144.

[58] Younesi, F. et al. Fibroblast and myofibroblast activation in normal tissue repair and fibrosis. Nat. Rev. Mol. Cell Biol. (2024).

[59] Angadi P, et al.. Evaluation of myofibroblasts in oral submucous fibrosis: correlation with disease severity. J. Oral. Pathol. Med., 2011, 40: 208-213.

[60] Yu, C. H. et al. LINC00312/YBX1 axis regulates myofibroblast activities in oral submucous fibrosis. Int. J. Mol. Sci. 21 (2020).

[61] Meng XM, et al.. TGF-β: the master regulator of fibrosis. Nat. Rev. Nephrol., 2016, 12: 325-338.

[62] Khan I, et al.. Activation of TGF-β pathway by areca nut constituents: a possible cause of oral submucous fibrosis. PLoS One, 2012, 7: e51806.

[63] Pant I, et al.. Role of areca nut induced JNK/ATF2/Jun axis in the activation of TGF-β pathway in precancerous oral submucous fibrosis. Sci. Rep., 2016, 6. 34314

[64] Chang JZ, et al.. EGCG blocks TGFβ1-induced CCN2 by suppressing JNK and p38 in buccal fibroblasts. Clin. Oral. Investig., 2013, 17: 455-461.

[65] Chang YC, et al.. Elevated vimentin expression in buccal mucosal fibroblasts by arecoline in vitro as a possible pathogenesis for oral submucous fibrosis. Oral. Oncol., 2002, 38: 425-430.

[66] Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat. Rev. Nephrol., 2011, 7: 684-696.

[67] Chang YC, et al.. Arecoline-induced myofibroblast transdifferentiation from human buccal mucosal fibroblasts is mediated by ZEB1. J. Cell Mol. Med., 2014, 18: 698-708.

[68] Chang MC, et al.. Areca nut-induced buccal mucosa fibroblast contraction and its signaling: a potential role in oral submucous fibrosis-a precancer condition. Carcinogenesis, 2013, 34: 1096-1104.

[69] Deng YT, et al.. Arecoline-stimulated connective tissue growth factor production in human buccal mucosal fibroblasts: Modulation by curcumin. Oral. Oncol., 2009, 45: e99-e105.

[70] Yeh MC, et al.. Low-power laser irradiation inhibits arecoline-induced fibrosis: an in vitro study. Int J. Oral. Sci., 2017, 9: 38-42.

[71] Yu CC, et al.. Aberrant SSEA-4 upregulation mediates myofibroblast activity to promote pre-cancerous oral submucous fibrosis. Sci. Rep., 2016, 6. 37004

[72] Yu CC, et al.. Targeting lncRNA H19/miR-29b/COL1A1 axis impedes myofibroblast activities of precancerous oral submucous fibrosis. Int. J. Mol. Sci., 2021, 22: 2216.

[73] Lee YH, et al.. Inhibition of lncRNA HOTTIP ameliorated myofibroblast activities and inflammatory cytokines in oral submucous fibrosis. J. Formos. Med. Assoc., 2021, 120: 1188-1193.

[74] Xia L, et al.. Arecoline and oral keratinocytes may affect the collagen metabolism of fibroblasts. J. Oral. Pathol. Med., 2009, 38: 422-426.

[75] Tsai CH, et al.. Raised keratinocyte growth factor-1 expression in oral submucous fibrosis in vivo and upregulated by arecoline in human buccal mucosal fibroblasts in vitro. J. Oral. Pathol. Med., 2005, 34: 100-105.

[76] Bishen KA, et al.. The role of basic fibroblast growth factor in oral submucous fibrosis pathogenesis. J. Oral. Pathol. Med., 2008, 37: 402-411.

[77] Lee YH, et al.. Elevation of Twist expression by arecoline contributes to the pathogenesis of oral submucous fibrosis. J. Formos. Med. Assoc., 2016, 115: 311-317.

[78] Tsai CC, et al.. Deficiency in collagen and fibronectin phagocytosis by human buccal mucosa fibroblasts in vitro as a possible mechanism for oral submucous fibrosis. J. Oral. Pathol. Med., 1999, 28: 59-63.

[79] Groeger S, et al.. Oral mucosal epithelial cells. Front Immunol., 2019, 10: 208.

[80] Feng Y, et al.. Research on inhibition of areca nut extract on human buccal keratinocytes. West Chin. J. Stomatol, 1999, 17: 233-235

[81] Zhou ZS, et al.. Arecoline suppresses HaCaT cell proliferation through cell cycle regulatory molecules. Oncol. Rep., 2013, 29: 2438-2444.

[82] Thangjam GS, et al.. Regulation of oxidative-stress responsive genes by arecoline in human keratinocytes. J. Periodontal Res., 2009, 44: 673-682.

[83] Chang MC, et al.. The induction of prostaglandin E2 production, interleukin-6 production, cell cycle arrest, and cytotoxicity in primary oral keratinocytes and KB cancer cells by areca nut ingredients is differentially regulated by MEK/ERK activation. J. Biol. Chem., 2004, 279: 50676-50683.

[84] Li L, et al.. Arecoline suppresses epithelial cell viability by upregulating tropomyosin-1 through the transforming growth factor-β/Smad pathway. Pharm. Biol., 2020, 58: 1244-1251.

[85] Gu L, et al.. Arecoline suppresses epithelial cell viability through the Akt/mTOR signaling pathway via upregulation of PHLPP2. Toxicology, 2019, 419: 32-39.

[86] Shetty SS, et al.. Signaling pathways promoting epithelial mesenchymal transition in oral submucous fibrosis and oral squamous cell carcinoma. Jpn. Dent. Sci. Rev., 2020, 56: 97-108.

[87] Das RK, et al.. Epithelio-mesenchymal transitional attributes in oral sub-mucous fibrosis. Exp. Mol. Pathol., 2013, 95: 259-269.

[88] Hu X, et al.. Overexpression of DEC1 in the epithelium of OSF promotes mesenchymal transition via activating FAK/Akt signal axis. J. Oral. Pathol. Med., 2022, 51: 780-790.

[89] Gao Y, et al.. Expression of transforming growth factor beta 1 in keratinocytes of oral submucous fibrosis tissue. Chin. J. Stomatol., 1997, 32: 239-241

[90] Yang X, et al.. Stromal thrombospondin 1 suppresses angiogenesis in oral submucous fibrosis. Int. J. Oral. Sci., 2024, 16: 17.

[91] Li LJ, P.X X. The OSF ultrastructure study of danshen root prior-treatment and post-treatment. J. Clin. Stomatol., 2008, 24: 751-752

[92] Thakkannavar SS, et al.. Histochemical and immunohistochemical analysis of collagen fibers and microvascular density in various grades of oral submucous fibrosis. Iran. J. Pathol., 2019, 14: 127-134.

[93] Tekade SA, et al.. Early stage oral submucous fibrosis is characterized by increased vascularity as opposed to advanced stages. J. Clin. Diagn. Res., 2017, 11: Zc92-zc96

[94] Tseng SK, et al.. Arecoline induced cell cycle arrest, apoptosis, and cytotoxicity to human endothelial cells. Clin. Oral. Investig., 2012, 16: 1267-1273.

[95] Li N, et al.. Cys-X-Cys ligand 9 might be an immunological factor in the pathogenesis of oral submucous fibrosis and its concomitant oral lichenoid lesion. Clin. Oral. Investig., 2013, 17: 1251-1258.

[96] Ullah M, et al.. Arecoline increases basic fibroblast growth factor but reduces expression of IL-1, IL-6, G-CSF and GM-CSF in human umbilical vein endothelium. J. Oral. Pathol. Med., 2015, 44: 591-601.

[97] Phatak AG. Oral submucous fibrosis-a chronic disseminated intravascular coagulation syndrome with local coagulopathy. Gut, 1993, 34: 713.

[98] Fang C, et al.. The pathological damage of microvessels in oral submucosal fibrosis. Chin. J. Mod. Med., 1996, 6: 72-73

[99] Yang SF, et al.. The upregulation of type I plasminogen activator inhibitor in oral submucous fibrosis. Oral. Oncol., 2003, 39: 367-372.

[100] Wang Y, et al.. Oxidative-protective effect of nuclear receptor coactivator 7 on arecoline-induced endothelial-to-mesenchymal transition. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radio., 2020, 130: 565-573.

[101] Liping W, et al.. Immunopathogenesis of oral submucous fibrosis by chewing the areca nut. J. Leukoc. Biol., 2021, 111: 469-476

[102] Matthias M. Inflammation and fibrosis. Matrix Biol., 2017, 68-69: 106-121

[103] Misharin AV, et al.. Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span. J. Exp. Med., 2017, 214: 2387-2404.

[104] Krenkel O, et al.. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology, 2018, 67: 1270-1283.

[105] Xu L, et al.. Tubular GM-CSF promotes late MCP-1/CCR2-mediated fibrosis and inflammation after ischemia/reperfusion injury. J. Am. Soc. Nephrol., 2019, 30: 1825-1840.

[106] Pereira T, et al.. Quantitative evaluation of macrophage expression using CD68 in oral submucous fibrosis: an immunohistochemical study. Ann. Med. Health Sci. Res., 2015, 5: 435-441.

[107] Brody SL, et al.. Chemokine receptor 2-targeted molecular imaging in pulmonary fibrosis. a clinical trial. Am. J. Respir. Crit. Care Med., 2021, 203: 78-89.

[108] Sarode G, et al.. Myofibroblasts could be recruited in a chemokine (C-C motif) ligand 2-dependent manner in pathogenesis of oral submucous fibrosis. J. Oral. Pathol. Med., 2017, 46: 443-447.

[109] H X, et al.. Expression of chemokines CCR 2 and CXCL 9 in oral submucous fibrosis. J. Clin. Stomatol., 2012, 28: 657-659

[110] Sabarinath B, et al.. Immunohistochemical evaluation of mast cells and vascular endothelial proliferation in oral submucous fibrosis. Indian J. Dent. Res., 2011, 22: 116-121.

[111] Yadav A, et al.. Altered immunohistochemical expression of mast cell tryptase and chymase in the pathogenesis of oral submucous fibrosis and malignant transformation of the overlying epithelium. PLoS One, 2014, 9: e98719.

[112] Pillai MR, et al.. Interferon activation of latent natural killer cells and alteration in kinetics of target cell lysis: clinical implications for oral precancerous lesions. Oral. Surg. Oral. Med. Oral. Pathol., 1990, 70: 458-461.

[113] Liu S, et al.. Skewed Th17/Treg balance during progression and malignant transformation of oral submucous fibrosis. Oral. Dis., 2022, 28: 2119-2130.

[114] Wang L, et al.. Cytokines secreted by arecoline activate fibroblasts that affect the balance of TH17 and Treg. J. Oral. Pathol. Med., 2020, 49: 156-163.

[115] Zhao X, et al.. Th17 cell-derived amphiregulin promotes colitis-associated intestinal fibrosis through activation of mTOR and MEK in intestinal myofibroblasts. Gastroenterology, 2023, 164: 89-102.

[116] Celada LJ, et al.. PD-1 up-regulation on CD4(+) T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production. Sci. Transl. Med., 2018, 10: eaar8356.

[117] S Y W, et al.. DPSCs regulate epithelial-T cell interactions in oral submucous fibrosis. Stem Cell Res. Ther., 2024, 15: 113.

[118] Auluck A, et al.. Oral submucous fibrosis, a clinically benign but potentially malignant disease: report of 3 cases and review of the literature. J. Can. Dent. Assoc., 2008, 74: 735-740

[119] Shakunthala GK, et al.. Role of oxidative stress in the pathogenesis of oral submucous fibrosis: a preliminary prospective study. Contemp. Clin. Dent., 2015, 6: S172-S174.

[120] Illeperuma RP, et al.. Areca nut exposure increases secretion of tumor-promoting cytokines in gingival fibroblasts that trigger DNA damage in oral keratinocytes. Int. J. Cancer, 2015, 137: 2545-2557.

[121] Chou MY, et al.. Depletion of miR-155 hinders the myofibroblast activities and reactive oxygen species generation in oral submucous fibrosis. J. Formos. Med. Assoc., 2022, 121: 467-472.

[122] Rai V, et al.. Evaluation of oxidative stress and the microenvironment in oral submucous fibrosis. Heliyon, 2019, 5. e01502

[123] Gupta S, et al.. Role of oxidative stress and antioxidants in aetiopathogenesis and management of oral submucous fibrosis. Indian J. Clin. Biochem., 2004, 19: 138-141.

[124] Shetty SR, et al.. Malondialdehyde levels in oral sub mucous fibrosis: a clinicopathological and biochemical study. N. Am. J. Med. Sci., 2012, 4: 125-128.

[125] Bale R, et al.. Oral submucous fibrosis: A quantitative assessment of serum malondialdehyde, superoxide dismutase and correlation with clinical staging. J. Oral. Maxillofac. Pathol., 2017, 21: 41-45.

[126] Chatterjee R, et al.. Pathophysiological relationship between hypoxia associated oxidative stress, Epithelial-mesenchymal transition, stemness acquisition and alteration of Shh/ Gli-1 axis during oral sub-mucous fibrosis and oral squamous cell carcinoma. Eur. J. Cell Biol., 2021, 100. 151146

[127] You Y, et al.. Angiotensin (1-7) inhibits arecoline-induced migration and collagen synthesis in human oral myofibroblasts via inhibiting NLRP3 inflammasome activation. J. Cell Physiol., 2019, 234: 4668-4680.

[128] Yen CY, et al.. Arecoline-mediated inhibition of AMP-activated protein kinase through reactive oxygen species is required for apoptosis induction. Oral. Oncol., 2011, 47: 345-351.

[129] Hung TC, et al.. Hemeoxygenase-1 expression in response to arecoline-induced oxidative stress in human umbilical vein endothelial cells. Int J. Cardiol., 2011, 151: 187-194.

[130] Wong DY, et al.. Glutathione concentration in oral cancer tissues. Cancer Lett., 1994, 81: 111-116.

[131] Chang YC, et al.. Synergistic effects of nicotine on arecoline-induced cytotoxicity in human buccal mucosal fibroblasts. J. Oral. Pathol. Med, 2001, 30: 458-464.

[132] Pitiyage GN, et al.. Senescent mesenchymal cells accumulate in human fibrosis by a telomere-independent mechanism and ameliorate fibrosis through matrix metalloproteinases. J. Pathol., 2011, 223: 604-617.

[133] Pitiyage GN, et al.. Increased secretion of tissue inhibitors of metalloproteinases 1 and 2 (TIMPs -1 and -2) in fibroblasts are early indicators of oral sub-mucous fibrosis and ageing. J. Oral. Pathol. Med., 2012, 41: 454-462.

[134] James EL, et al.. Senescent human fibroblasts show increased glycolysis and redox homeostasis with extracellular metabolomes that overlap with those of irreparable DNA damage, aging, and disease. J. Proteome Res., 2015, 14: 1854-1871.

[135] Rehman A, et al.. Areca nut alkaloids induce irreparable DNA damage and senescence in fibroblasts and may create a favourable environment for tumour progression. J. Oral. Pathol. Med., 2016, 45: 365-372.

[136] Wang Z, et al.. Senescent epithelial cells remodel the microenvironment for the progression of oral submucous fibrosis through secreting TGF-β1. PeerJ, 2023, 11. e15158

[137] Sharma M, et al.. Emerging role of cellular senescence in the pathogenesis of oral submucous fibrosis and its malignant transformation. Head. Neck, 2021, 43: 3153-3164.

[138] Aguilera MO, et al.. Chronic infections: a possible scenario for autophagy and senescence cross-talk. Cells, 2018, 7: 162.

[139] Migneault F, et al.. Autophagy, tissue repair, and fibrosis: a delicate balance. Matrix Biol., 2021, 100-101: 182-196.

[140] Vescarelli E, et al.. Autophagy activation is required for myofibroblast differentiation during healing of oral mucosa. J. Clin. Periodontol., 2017, 44: 1039-1050.

[141] Li J, et al.. Autophagy mediates oral submucous fibrosis. Exp. Ther. Med., 2016, 11: 1859-1864.

[142] Zhu B, et al.. Role of autophagy and apoptosis in atrophic epithelium in oral submucous fibrosis. J. Oral. Sci., 2020, 62: 184-188.

[143] Dai Z, et al.. Role of autophagy induced by arecoline in angiogenesis of oral submucous fibrosis. Arch. Oral. Biol., 2019, 102: 7-15.

[144] Zhong X, et al.. Oral microbiota alteration associated with oral cancer and areca chewing. Oral. Dis., 2021, 27: 226-239.

[145] Zhang WL, et al.. Who is who in oral cancer?. Exp. Cell Res., 2019, 384. 111634

[146] Chen L, et al.. Potential role of host microbiome in areca nut-associated carcinogenesis and addiction. Molecules, 2022, 27: 8171.

[147] Sharma M, et al.. Limited mouth opening in oral submucous fibrosis: reasons, ramifications, and remedies. J. Oral. Pathol. Med., 2017, 46: 424-430.

[148] Shih YH, et al.. Oral submucous fibrosis: a review on etiopathogenesis, diagnosis, and therapy. Int J. Mol. Sci., 2019, 20: 2940.

[149] Guruprasad R, et al.. Serum vitamin C and iron levels in oral submucous fibrosis. Indian J. Dent., 2014, 5: 81-85.

[150] Yadav A, et al.. Estimation of serum zinc, copper, and iron in the patients of oral submucous fibrosis. Natl J. Maxillofac. Surg., 2015, 6: 190-193.

[151] Jani YV, et al.. Evaluation of role of trace elements in oral submucous fibrosis patients: a study on Gujarati population. J. Oral. Maxillofac. Pathol., 2017, 21: 455.

[152] Kode MA, et al.. Estimation of the serum and the salivary trace elements in OSMF patients. J. Clin. Diagn. Res., 2013, 7: 1215-1218

[153] Mishra S, et al.. Estimation of salivary and serum lactate dehydrogenase in oral submucous fibrosis. J. Int Soc. Prev. Community Dent., 2018, 8: 289-295.

[154] Aggarwal A, et al.. Estimation of serum beta carotene levels in patients with oral submucous fibrosis in India. J. Oral. Sci., 2011, 53: 427-431.

[155] Paul RR, et al.. A novel wavelet neural network based pathological stage detection technique for an oral precancerous condition. J. Clin. Pathol., 2005, 58: 932-938.

[156] Haris PS, et al.. Autofluorescence spectroscopy for the in vivo evaluation of oral submucous fibrosis. Photomed. Laser Surg., 2009, 27: 757-761.

[157] Chaturvedi P, et al.. Fluorescence spectroscopy for noninvasive early diagnosis of oral mucosal malignant and potentially malignant lesions. J. Cancer Res. Ther., 2010, 6: 497-502.

[158] Sivabalan S, et al.. In vivo native fluorescence spectroscopy and nicotinamide adinine dinucleotide/flavin adenine dinucleotide reduction and oxidation states of oral submucous fibrosis for chemopreventive drug monitoring. J. Biomed. Opt., 2010, 15: 017010.

[159] Wang CY, et al.. PLS-ANN-based classification model for oral submucous fibrosis and oral carcinogenesis. Lasers Surg. Med., 2003, 32: 318-326.

[160] Vedeswari CP, et al.. In vivo autofluorescence characteristics of pre- and post-treated oral submucous fibrosis: a pilot study. Indian J. Dent. Res., 2009, 20: 261-267.

[161] Kumar K, et al.. Discrimination of oral submucous fibrosis (OSF) affected oral tissues from healthy oral tissues using multivariate analysis of in vivo fluorescence spectroscopic data: a simple and fast procedure for OSF diagnosis. Anal. Methods, 2013, 5: 3482-3489.

[162] Lee CK, et al.. Diagnosis of oral submucous fibrosis with optical coherence tomography. J. Biomed. Opt., 2009, 14: 054008.

[163] Rai V, et al.. Serum-based diagnostic prediction of oral submucous fibrosis using FTIR spectrometry. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2018, 189: 322-329.

[164] Manjunath K, et al.. Evaluation of oral submucous fibrosis using ultrasonographic technique: a new diagnostic tool. Indian J. Dent. Res, 2011, 22: 530-536.

[165] Grover S, et al.. A comparative study for selectivity of micronuclei in oral exfoliated epithelial cells. J. Cytol., 2012, 29: 230-235.

[166] Rajalalitha P, et al.. Molecular pathogenesis of oral submucous fibrosis-a collagen metabolic disorder. J. Oral. Pathol. Med., 2005, 34: 321-328.

[167] Gupta D, et al.. Oral submucous fibrosis-a new treatment regimen. J. Oral. Maxillofac. Surg., 1988, 46: 830-833.

[168] Kakar PK, et al.. Oral submucous fibrosis-treatment with hyalase. J. Laryngol. Otol., 1985, 99: 57-59.

[169] Bae-Harboe YS, et al.. Collagenase followed by compression for the treatment of earlobe keloids. Dermatol Surg., 2014, 40: 519-524.

[170] Akerman J, et al.. Treatment of Peyronie’s disease via preoperative intralesional collagenase clostridium histolyticum followed by placement of an inflatable penile prosthesis: the new standard of care?. Transl. Androl. Urol., 2017, 6: S822-s823.

[171] Lin HJ, et al.. Treatment of oral submucous fibrosis by collagenase: effects on oral opening and eating function. Oral. Dis., 2007, 13: 407-413.

[172] Villegas MR, et al.. Collagenase nanocapsules: an approach to fibrosis treatment. Acta Biomater., 2018, 74: 430-438.

[173] Borle RM, et al.. Management of oral submucous fibrosis: a conservative approach. J. Oral. Maxillofac. Surg., 1991, 49: 788-791.

[174] Singh M, et al.. Efficacy of hydrocortisone acetate/hyaluronidase vs triamcinolone acetonide/hyaluronidase in the treatment of oral submucous fibrosis. Indian J. Med Res., 2010, 131: 665-669

[175] Sirsat SM, et al.. Subepithelial changes in oral submucous fibrosis. Acta Pathol. Microbiol. Scand., 1967, 70: 161-173.

[176] Kar IB, et al.. A rare ocular complication following treatment of oral submucous fibrosis with steroids. Natl J. Maxillofac. Surg., 2011, 2: 93-95.

[177] Haque MF, et al.. Interferon gamma (IFN-gamma) may reverse oral submucous fibrosis. J. Oral. Pathol. Med., 2001, 30: 12-21.

[178] Krishnamoorthy B, et al.. Management of oral submucous fibrosis by two different drug regimens: a comparative study. Dent. Res J., 2013, 10: 527-532

[179] Tai YS, et al.. Oral administration of milk from cows immunized with human intestinal bacteria leads to significant improvements of symptoms and signs in patients with oral submucous fibrosis. J. Oral. Pathol. Med., 2001, 30: 618-625.

[180] Lai DR, et al.. Clinical evaluation of different treatment methods for oral submucous fibrosis. A 10-year experience with 150 cases. J. Oral. Pathol. Med., 1995, 24: 402-406.

[181] Sharma JK, et al.. Clinical experience with the use of peripheral vasodilator in oral disorders. Int. J. Oral. Maxillofac. Surg., 1987, 16: 695-699.

[182] Bhadage CJ, et al.. Vasodilator isoxsuprine alleviates symptoms of oral submucous fibrosis. Clin. Oral. Investig., 2013, 17: 1375-1382.

[183] Rajendran R, et al.. Pentoxifylline therapy: a new adjunct in the treatment of oral submucous fibrosis. Indian J. Dent. Res., 2006, 17: 190-198.

[184] Liu J, et al.. Evaluating the efficacy of pentoxifylline in the treatment of oral submucous fibrosis: a meta-analysis. Oral. Dis., 2018, 24: 706-716.

[185] Li X, et al.. Clinical treatment observation of tea pigment for oral submucous fibrosis. West Chin. J. Stomatol, 1998, 16: 50-52

[186] Kumar A, et al.. Efficacy of lycopene in the management of oral submucous fibrosis. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radio. Endod., 2007, 103: 207-213.

[187] Guo J, et al.. Efficacy of lycopene in the treatment of oral submucous fibrosis: a meta-analysis of randomized controlled trials. J. Evid. Based Dent. Pract., 2020, 20. 101471

[188] Mulk BS, et al.. Spirulina and pentoxyfilline - a novel approach for treatment of oral submucous fibrosis. J. Clin. Diagn. Res., 2013, 7: 3048-3050

[189] Alam S, et al.. Efficacy of aloe vera gel as an adjuvant treatment of oral submucous fibrosis. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radio., 2013, 116: 717-724.

[190] Sudarshan R, et al.. Aloe vera in the treatment for oral submucous fibrosis - a preliminary study. J. Oral. Pathol. Med., 2012, 41: 755-761.

[191] Zheng L, et al.. Tanshinone suppresses arecoline-induced epithelial-mesenchymal transition in oral submucous fibrosis by epigenetically reactivating the p53 pathway. Oncol. Res., 2018, 26: 483-494.

[192] Dai JP, et al.. Inhibition of tanshinone IIA, salvianolic acid A and salvianolic acid B on Areca nut extract-induced oral submucous fibrosis in vitro. Molecules, 2015, 20: 6794-6807.

[193] Vinay KH, et al.. Efficacy of curcumin in the treatment for oral submucous fibrosis—a randomized clinical trial. J. Oral. Maxillofac. Pathol., 2015, 19: 145-152.

[194] Guo ZX, et al.. A biomaterial-based therapy using a sodium hyaluronate/bioglass composite hydrogel for the treatment of oral submucous fibrosis. Acta Biomater., 2023, 157: 639-654.

[195] Han B, et al.. Adipose-derived stem cell-derived extracellular vesicles inhibit the fibrosis of fibrotic buccal mucosal fibroblasts via the microRNA-375/FOXF1 Axis. Stem Cells Int, 2021, 2021. 9964159

[196] Neighbors M, et al.. Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials. Lancet Respir. Med., 2018, 6: 615-626.

[197] Volkmann ER, et al.. Treatment of systemic sclerosis-related interstitial lung disease: a review of existing and emerging therapies. Ann. Am. Thorac. Soc., 2016, 13: 2045-2056.

[198] Cardoneanu A, et al.. Targeting systemic sclerosis from pathogenic mechanisms to clinical manifestations: why IL-6?. Biomedicines, 2022, 10: 318.

[199] Warnakulasuriya S, et al.. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J. Oral. Pathol. Med., 2007, 36: 575-580.

[200] Raju KL, et al.. Expression of hTERT in oral submucous fibrosis and oral squamous cell carcinoma—an immunohistochemical analysis. Pathol. Oncol. Res., 2020, 26: 1573-1582.

[201] Lunde ML, et al.. Profiling of chromosomal changes in potentially malignant and malignant oral mucosal lesions from South and South-East Asia using array-comparative genomic hybridization. Cancer Genom. Proteom., 2014, 11: 127-140

[202] Dave BJ, et al.. Role of areca nut consumption in the cause of oral cancers. A cytogenetic assessment. Cancer, 1992, 70: 1017-1023.

[203] Lin YC, et al.. Polymorphisms of COX-2 -765G>C and p53 codon 72 and risks of oral squamous cell carcinoma in a Taiwan population. Oral. Oncol., 2008, 44: 798-804.

[204] Teh MT, et al.. Fingerprinting genomic instability in oral submucous fibrosis. J. Oral. Pathol. Med., 2008, 37: 430-436.

[205] Zhou S, et al.. Expression and promoter methylation of Wnt inhibitory factor-1 in the development of oral submucous fibrosis. Oncol. Rep., 2015, 34: 2636-2642.

[206] Zhou S, et al.. Exosome-derived long non-coding RNA ADAMTS9-AS2 suppresses progression of oral submucous fibrosis via AKT signalling pathway. J. Cell Mol. Med., 2021, 25: 2262-2273.

[207] Wang J, et al.. The circEPSTI1/mir-942-5p/LTBP2 axis regulates the progression of OSCC in the background of OSF via EMT and the PI3K/Akt/mTOR pathway. Cell Death Dis., 2020, 11. 682

[208] Zhou S, et al.. The phosphorylation of survivin Thr34 by p34cdc2 in carcinogenesis of oral submucous fibrosis. Oncol. Rep., 2008, 20: 1085-1091

[209] Zhou SH, et al.. Molecules of G(2)/M phase and the phosphorylation of survivin in the carcinogenesis of oral submucosal fibrosis. Chin. J. Stomatol., 2008, 43: 709-712

[210] Mallick S, et al.. Human oral cancers have altered expression of Bcl-2 family members and increased expression of the anti-apoptotic splice variant of Mcl-1. J. Pathol., 2009, 217: 398-407.

[211] Mishra R, et al.. Cyclin D1 expression and its possible regulation in chewing tobacco mediated oral squamous cell carcinoma progression. Arch. Oral. Biol., 2009, 54: 917-923.

[212] Haniffa AM, et al.. Expression pattern of p63 in oral epithelial lesions and submucous fibrosis associated with betel-quid chewing in Sri Lanka. Med. Mol. Morphol., 2007, 40: 203-207.

[213] Bag S, et al.. Computational analysis of p63(+) nuclei distribution pattern by graph theoretic approach in an oral pre-cancer (sub-mucous fibrosis). J. Pathol. Inf., 2013, 4: 35.

[214] Pereira T, et al.. Qualitative expression of hypoxia-inducible factor-1α in malignant transformation of oral submucous fibrosis: An immunohistochemical study. J. Oral. Maxillofac. Pathol., 2020, 24: 106-112.

[215] Chaudhary M, et al.. The domino effect: Role of hypoxia in malignant transformation of oral submucous fibrosis. J. Oral. Maxillofac. Pathol., 2015, 19: 122-127.

[216] Tilakaratne WM, et al.. Upregulation of HIF-1alpha in malignant transformation of oral submucous fibrosis. J. Oral. Pathol. Med., 2008, 37: 372-377.

[217] Silva LC, et al.. CD1a+ and CD207+ cells are reduced in oral submucous fibrosis and oral squamous cell carcinoma. Med Oral. Patol. Oral. Cir. Bucal, 2020, 25: e49-e55.

[218] Hosur MB, et al.. Evaluation of immunohistochemical expression of epithelial- mesenchymal transition markers E-cadherin, Twist and Snail in oral submucous fibrosis and their possible association with malignant transformation. J. Oral. Maxillofac. Pathol., 2021, 25: 97-104.

[219] Sarode SC, et al.. Dysplastic features relevant to malignant transformation in atrophic epithelium of oral submucous fibrosis: a preliminary study. J. Oral. Pathol. Med, 2018, 47: 410-416.

[220] Sharma M, et al.. Loss of oral mucosal stem cell markers in oral submucous fibrosis and their reactivation in malignant transformation. Int. J. Oral. Sci., 2020, 12: 23.

[221] Sharma M, et al.. Role of Yes-associated protein and transcriptional coactivator with PDZ-binding motif in the malignant transformation of oral submucous fibrosis. Arch. Oral. Biol., 2021, 128. 105164

[222] Gandhi P, et al.. Evaluation of myofibroblasts in oral submucous fibrosis and oral squamous cell carcinoma: The pathogenesis and correlation. Dent. Res. J., 2017, 14: 314-320.

[223] Zhang P, et al.. Molecular mechanisms of malignant transformation of oral submucous fibrosis by different betel quid constituents-does fibroblast senescence play a role?. Int. J. Mol. Sci., 2022, 23: 1637.

[224] Shan-Shan Z, et al.. A rat model of oral submucous fibrosis induced by bleomycin. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radio., 2016, 122: 216-223.

[225] Qi-Tao W, et al.. Development of a mouse model of arecoline-induced oral mucosal fibrosis. Asian Pac. J. Trop. Med., 2017, 10: 1177-1184.

[226] Pal S, et al.. Plant leads for mitigation of oral submucous fibrosis: current scenario and future prospect. Oral Dis, 2022, 30: 80-99.

[227] McCallum G, et al.. The gut microbiota and its biogeography. Nat. Rev. Microbiol., 2023, 22: 105-118.

Funding

National Key Research and Development Program of China (2022YFC2402900);The Joint Funds of the Hunan Provincial Natural Science Foundation (2023JJ60509);The Science and Technology Talent Support Project of the Hunan Provincial Science Popularization Special Project (2023TJ-Z08),

Hunan Provincial Innovation Foundation for Postgraduate(2023ZZTS0218)

The Postgraduate Independent Exploration Innovation Fund of the Central South University (2023ZZTS0987).,

National Natural Science Foundation of China (National Science Foundation of China)(52103327)

RIGHTS & PERMISSIONS

The Author(s)